The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis
- PDF / 313,745 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 3 Downloads / 217 Views
ORIGINAL CONTRIBUTIONS
The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis Kornpong Vantanasiri 1 & Reem Matar 2 & Azizullah Beran 2 & Veeravich Jaruvongvanich 2
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Background Intragastric balloons have been used to bridge the obesity treatment gap with the benefits of being minimally invasive but still required endoscopy. The Elipse intragastric balloon (EIGB) is a swallowable balloon that is spontaneously excreted through a natural orifice at approximately 16 weeks. Several concerns exist, including the treatment efficacy and risk of bowel obstruction. Our meta-analysis aimed to evaluate the efficacy and safety of EIGB. Methods A literature search was performed from several databases from database inception to November 2019. Eligible studies must report percent total weight loss (%TWL) after completion of treatment and adverse events. The pooled means and proportions of our data were analyzed using random effects model, generic inverse variance method. Results Six studies involving 2013 unique patients met our eligibility criteria and were included. The mean baseline BMI ranged from 30.6 to 36.2. The pooled early removal rate was 2.3% (95% CI, 1.1–3.5%; I2 31%). The pooled %TWL after completion of treatment (4–6 months) was 12.8% (95% CI, 11.6–13.9%; I2 83%) and at 12 months was 10.9% (95% CI, 5.0–16.9%, I2 98%). For serious adverse events, three patients had small bowel obstruction, and one patient had gastric perforation requiring surgery. Early expulsion by emesis and early deflation were seen in 3 and 9 patients, respectively. Conclusions This meta-analysis demonstrates that EIGB is a safe device offering an effective weight loss that warrants further studies for its long-term weight loss outcomes. Severe adverse events are rare, and the rate of early removal is low. Keywords Gastric balloon . Procedureless Gastric Balloon . Elipse Intragastric Balloon
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11695-020-04522-3) contains supplementary material, which is available to authorized users. * Veeravich Jaruvongvanich [email protected] Kornpong Vantanasiri [email protected] Reem Matar [email protected] Azizullah Beran [email protected] 1
Department of Medicine, University of Minnesota, Minnesota, USA
2
Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Minnesota, USA
Obesity is becoming a highly debated topic in recent years given multiple associations with serious health conditions [1, 2] and its continuously increasing prevalence, which was already up to 40 % among US adults in 2016 [3]. Bariatric surgery is considered in patients with obesity class III or class II with obesity-related comorbidities and proven to be the most effective and sustainable treatment of obesity [4]. Multiple techniques of bariatric interventions have been introduced, including endoscop
Data Loading...
